The researchers also observed that SCLC immunocompetent lung tumors treated with the CHK1 inhibitor exhibited a notable increase in the infiltration of CD3+ total T cells and CD8+ T cells. This evidence concerns the gene CHEK1 and small cell lung carcinoma.